U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H21NO2
Molecular Weight 259.344
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PROPRANOLOL

SMILES

CC(C)NCC(COc1cccc2ccccc21)O

InChI

InChIKey=AQHHHDLHHXJYJD-UHFFFAOYSA-N
InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C16H21NO2
Molecular Weight 259.344
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25198737 https://www.ncbi.nlm.nih.gov/pubmed/2865152

Propranolol is a nonselective, beta-adrenergic receptor-blocking agent possessing no other autonomic nervous system activity. At dosages greater than required for beta blockade, propranolol also exerts a quinidine-like or anesthetic-like membrane action, which affects the cardiac action potential. Among the factors that may be involved in contributing to the antihypertensive action include: (1) decreased cardiac output, (2) inhibition of renin release by the kidneys, and (3) diminution of tonic sympathetic nerve outflow from vasomotor centers in the brain. Although total peripheral resistance may increase initially, it readjusts to or below the pretreatment level with chronic use of propranolol. Effects of propranolol on plasma volume appear to be minor and somewhat variable. In angina pectoris, propranolol generally reduces the oxygen requirement of the heart at any given level of effort by blocking the catecholamine-induced increases in the heart rate, systolic blood pressure, and the velocity and extent of myocardial contraction. Propranolol may increase oxygen requirements by increasing left ventricular fiber length, end diastolic pressure, and systolic ejection period. The net physiologic effect of beta-adrenergic blockade is usually advantageous and is manifested during exercise by delayed onset of pain and increased work capacity. Propranolol exerts its antiarrhythmic effects in concentrations associated with beta-adrenergic blockade, and this appears to be its principal antiarrhythmic mechanism of action. In dosages greater than required for beta blockade, propranolol also exerts a quinidine-like or anesthetic-like membrane action, which affects the cardiac action potential. The significance of the membrane action in the treatment of arrhythmias is uncertain. The mechanism of the anti-migraine effect of propranolol has not been established. Propranolol is indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Also is indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris; for the prophylaxis of common migraine headache. In addition, is used to improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Due to the high penetration across the blood–brain barrier, propranolol causes sleep disturbances such as insomnia and vivid dreams, and nightmares. Dreaming (rapid eye movement sleep, REM) was reduced and increased awakening.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
INDERAL LA

Approved Use

Propranolol hydrochloride extended-release capsules are indicated for the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride extended-release capsules are not indicated for the management of hypertensive emergencies. Due to Coronary Atherosclerosis Propranolol hydrochloride extended-release capsules are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Propranolol hydrochloride extended-release capsules are indicated for the prophylaxis of a common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Propranolol hydrochloride extended-release capsules improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.

Launch Date

5.43023989E11
Primary
INDERAL LA

Approved Use

Propranolol hydrochloride extended-release capsules are indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride extended-release capsules is not indicated in the management of hypertensive emergencies. Due to Coronary Atherosclerosis Propranolol hydrochloride extended-release capsules are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Propranolol hydrochloride extended-release capsules are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Propranolol hydrochloride extended-release capsules improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.

Launch Date

5.43023989E11
Preventing
INDERAL LA

Approved Use

Propranolol hydrochloride extended-release capsules are indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride extended-release capsules is not indicated in the management of hypertensive emergencies. Due to Coronary Atherosclerosis Propranolol hydrochloride extended-release capsules are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Propranolol hydrochloride extended-release capsules are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Propranolol hydrochloride extended-release capsules improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.

Launch Date

5.43023989E11
Primary
INDERAL LA

Approved Use

Propranolol hydrochloride extended-release capsules are indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride extended-release capsules is not indicated in the management of hypertensive emergencies. Due to Coronary Atherosclerosis Propranolol hydrochloride extended-release capsules are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Propranolol hydrochloride extended-release capsules are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Propranolol hydrochloride extended-release capsules improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.

Launch Date

5.43023989E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
147 ng/mL
40 mg single, sublingual
dose: 40 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
PROPRANOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
41 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPRANOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
161 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPRANOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
26 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPRANOLOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
47 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPRANOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
245 ng × h/mL
40 mg single, sublingual
dose: 40 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
PROPRANOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
79 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPRANOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.91 h
40 mg single, sublingual
dose: 40 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
PROPRANOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.41 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPRANOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely [IC50 >133 uM]
likely
likely
likely
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >1000 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no
no
no
yes [Activation 28.1838 uM]
yes [IC50 189 uM]
yes [IC50 4 uM]
yes [Inhibition 5.5 uM]
yes
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: Coadminstration of CYP1A2 inhibitors increased Propranolol plasma concentration. Coadministration of CYP1A2 inducers decreased Propranolol plasma concentration.
Page: (Label) 5, 7-8
major
yes (co-administration study)
Comment: Coadminstration of CYP2D6 inhibitors increased Propranolol plasma concentration.
Page: (Label) 5, 7-8
minor
yes (co-administration study)
Comment: Coadminstration of CYP2C19 inhibitors increased Propranolol plasma concentration. Coadministration of CYP2C19 inducers decreased Propranolol plasma concentration.
Page: (Label) 5, 7-8
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
weak
weak
weak
weak
yes [Km 11.8 uM]
yes [Km 154 uM]
yes [Km 434 uM]
yes
yes
yes
yes
yes
yes
yes
Tox targets
PubMed

PubMed

TitleDatePubMed
Severe bradycardia after neostigmine in a patient taking propranolol to control paroxysmal atrial tachycardia.
1975 Feb
[Experimental anti-arrhythmic effects of a new beta-adrenergic receptor blocking agent, dl-l-(tert. butylamino)-3-[(2-propinyloxy)phenoxy]2-propanol hydrochloride (dl Kö 1400-Cl)].
1976 Jul
Altered baroreflex control of heart rate in bradykinin B2-receptor knockout mice.
1999 Dec
The effect of sodium bicarbonate on propranolol-induced cardiovascular toxicity in a canine model.
2000
Dystonia in a patient treated with propranolol and gabapentin.
2000 Apr
Low catecholamine concentrations protect adult rat ventricular myocytes against apoptosis through cAMP-dependent extracellular signal-regulated kinase activation.
2000 Dec
[Effects of nitrates and beta-blockers on platelet aggregation in patients with coronary heart disease].
2000 Feb
Platelet alpha2-adrenoceptor alterations in patients with essential hypertension are normalized after treatment with doxazosin but not propranolol.
2000 Feb
Involvement of central beta-adrenoceptors in the tachycardia induced by water immersion stress in rats.
2000 Jan
The combination of propranolol and magnesium does not prevent postoperative atrial fibrillation.
2000 Jan
Leukocytoclastic vasculitis: is propranolol implicated?
2000 Jul
Role of aortic nitric oxide synthase 3 (eNOS) in the systemic vasodilation of portal hypertension.
2000 Jul
Cerebellar Ataxia.
2000 May
Effects of prolonged propranolol treatment on left ventricular remodeling and oxidative stress after myocardial infarction in rats.
2000 May
Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a beta -adrenoreceptor/cAMP/protein kinase A pathway involving Src but independently of Erk1/2.
2000 May 5
[Effects of isoprenaline on apoptosis related gene expression in rat myocardium cells].
2000 Nov
[Recovery from pancytopenia and liver dysfunction after administration of thiamazole for hyperthyroidism].
2000 Nov
Catecholamines suppress leptin release from in vitro differentiated subcutaneous human adipocytes in primary culture via beta1- and beta2-adrenergic receptors.
2000 Sep
Protein phosphatase activity is increased in a rat model of long-term beta-adrenergic stimulation.
2000 Sep
Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia.
2001 Feb
Periovulatory changes in catfish ovarian oestradiol-17beta, oestrogen-2-hydroxylase and catechol-O-methyltransferase during GnRH analogue-induced ovulation and in vitro induction of oocyte maturation by catecholoestrogens.
2001 Feb
Cellular cholesterol efflux is modulated by phospholipid-derived signaling molecules in familial HDL deficiency/Tangier disease fibroblasts.
2001 Feb
Pharmacologic therapy for portal hypertension.
2001 Feb
Pharmacologic management of atrial fibrillation: current therapeutic strategies.
2001 Feb
Characterization of a novel cationic drug transporter in human retinal pigment epithelial cells.
2001 Feb
Asymmetric synthesis and preliminary evaluation of (R)- and (S)-[11C]bisoprolol, a putative beta1-selective adrenoceptor radioligand.
2001 Feb
Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells.
2001 Feb 1
Sympathetic control of nasal blood flow in the rat mediated by alpha(1)-adrenoceptors.
2001 Feb 16
Enhancement of memory consolidation in chicks by beta(3)-adrenoceptor agonists.
2001 Feb 16
Correlation of the electrical and intrinsic optical signals in the chicken spreading depression phenomenon.
2001 Feb 16
[Availability of antidotes in French emergency medical aid units].
2001 Feb 3
Daily variation of azygos and portal blood flow and the effect of propranolol administration once an evening in cirrhotics.
2001 Jan
Evidence for the binding of beta-adrenoceptor blockers to microsomal Na+/K+-ATPase in guinea pig heart preparations.
2001 Jan
Abolition of (-)-CGP 12177-evoked cardiostimulation in double beta1/beta2-adrenoceptor knockout mice. Obligatory role of beta1-adrenoceptors for putative beta4-adrenoceptor pharmacology.
2001 Jan
Oxygen consumption in patients with hyperthyroidism before and after treatment with beta-blockade versus thyrostatic treatment: a prospective randomized study.
2001 Jan
Amiodarone is safe and highly effective therapy for supraventricular tachycardia in infants.
2001 Jan
Adrenergic receptor activated ion transport in human fetal retinal pigment epithelium.
2001 Jan
alpha-Adrenoceptor stimulation-mediated negative inotropism and enhanced Na(+)/Ca(2+) exchange in mouse ventricle.
2001 Jan
Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction.
2001 Jan
Activation of extracellular signal-regulated kinases, NF-kappa B, and cyclic adenosine 5'-monophosphate response element-binding protein in lung neutrophils occurs by differing mechanisms after hemorrhage or endotoxemia.
2001 Jan 1
Changes in sensitivity of cholinoceptors and adrenoceptors during transhemispheric cortical reorganisation in rat SmI.
2001 Jan 12
Colon and anal sphincter contractions evoked by microstimulation of the sacral spinal cord in cats.
2001 Jan 19
Effects of mono-, di- and tri-hydroxybenzoic acids on the nitrosation of propranolol: structure-activity relationship.
2001 Jan 25
Effect of carvedilol on atrioventricular conduction in the ischemic heart.
2001 Jan 26
Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome.
2001 Jan 26
Ion-exchange fibers and drugs: an equilibrium study.
2001 Jan 29
Misrepresentation and miscommunication of teratogenic risk of drugs; analysis of three highly publicized international cases.
2001 Jan-Feb
Evidence of alpha-adrenoceptor-mediated chronotropic action in children.
2001 Jan-Feb
Propranolol rapidly reverses paralysis, hypokalemia, and hypophosphatemia in thyrotoxic periodic paralysis.
2001 Mar
Central corticotropin releasing factor (CRF) and adrenergic receptors mediate hemodynamic responses to cocaine.
2001 Mar 2
Patents

Sample Use Guides

Hypertension: The usual initial dosage is 80 mg capsules once daily, whether used alone or added to a diuretic. The dosage may be increased to 120 mg once. Angina Pectoris: Starting with 80 mg capsules once daily, dosage should be gradually increased at three- to seven-day intervals until optimal response is obtained. Although individual patients may respond at any dosage level, the average optimal dosage appears to be 160 mg once daily. Migraine: The initial oral dose is 80 mg capsules once daily. The usual effective dose range is 160 to 240 mg once daily. Hypertrophic Subaortic Stenosis: The usual dosage is 80 to 160 mg capsules once daily.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment:: Propranolol dose-dependently inhibited growth factor-induced proliferation of cultured human umbilical vein endothelial cells (HUVECs) through a G₀/G₁ phase cell cycle arrest. This was correlated to decreased cyclin D1, cyclin D3, and cyclin-dependent kinase CDK6 protein levels, while increases in the CDK inhibitors p15(INK4B), p21(WAF1/Cip1) and p27(Kip1) were observed.
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 16:14:15 UTC 2021
Edited
by admin
on Sat Jun 26 16:14:15 UTC 2021
Record UNII
9Y8NXQ24VQ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PROPRANOLOL
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
INNOPRAN XL
Common Name English
(+/-)-PROPRANOLOL
Common Name English
REDUCOR
Common Name English
PROPRANOLOL [VANDF]
Common Name English
AY-64043-
Code English
PROPRANOLOL [MI]
Common Name English
.BETA.-PROPRANOLOL
Common Name English
DL-PROPRANOLOL
Common Name English
2-PROPANOL, 1-((1-METHYLETHYL)AMINO)-3-(1-NAPHTHALENYLOXY)-
Systematic Name English
PROPRANOLOL [WHO-DD]
Common Name English
1-((1-METHYLETHYL)AMINO)-3-(1-NAPHTHALENYLOXY)-2-PROPANOL
Systematic Name English
PROPRASYLYT
Common Name English
EUPROVASIN
Common Name English
BETALONG
Common Name English
PROPRANOLOL [INN]
Common Name English
Classification Tree Code System Code
WHO-VATC QC07AA05
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
WHO-ATC C07FA05
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
NDF-RT N0000175556
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
LIVERTOX 810
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
FDA ORPHAN DRUG 266708
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
NCI_THESAURUS C29576
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
EU-Orphan Drug EU/3/16/1805
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
WHO-VATC QC07FA05
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
WHO-VATC QC07BA05
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
FDA ORPHAN DRUG 703319
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 7.2
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
NDF-RT N0000000161
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
WHO-ATC C07BA05
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
WHO-ATC C07FX01
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
FDA ORPHAN DRUG 475715
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
WHO-ATC C07AA05
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
FDA ORPHAN DRUG 484315
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
Code System Code Type Description
DRUG BANK
DB00571
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
PRIMARY
IUPHAR
564
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
PRIMARY
CAS
525-66-6
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
PRIMARY
ChEMBL
CHEMBL27
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
PRIMARY
MERCK INDEX
M9223
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
PRIMARY Merck Index
FDA UNII
9Y8NXQ24VQ
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
PRIMARY
WIKIPEDIA
PROPRANOLOL
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
PRIMARY
INN
1940
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
PRIMARY
ECHA (EC/EINECS)
235-867-6
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
ALTERNATIVE
CAS
13013-17-7
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
SUPERSEDED
PUBCHEM
4946
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
PRIMARY
LACTMED
Propranolol
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
PRIMARY
MESH
D011433
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
PRIMARY
ECHA (EC/EINECS)
208-378-0
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
PRIMARY
EPA CompTox
525-66-6
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
PRIMARY
NCI_THESAURUS
C62073
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
PRIMARY
DRUG CENTRAL
2303
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
PRIMARY
EVMPD
SUB10119MIG
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
PRIMARY
RXCUI
8787
Created by admin on Sat Jun 26 16:14:16 UTC 2021 , Edited by admin on Sat Jun 26 16:14:16 UTC 2021
PRIMARY RxNorm
Related Record Type Details
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
COMPETITIVE INHIBITOR
Ki
TRANSPORTER -> INHIBITOR
TARGET -> INHIBITOR
Ki
Related Record Type Details
METABOLITE ACTIVE -> PARENT
In vitro studies have indicated that the aromatic hydroxylation of propranolol is catalyzed mainly by polymorphic CYP2D6.
METABOLITE -> PARENT
MAJOR
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
In vitro studies have indicated that the aromatic hydroxylation of propranolol is catalyzed mainly by polymorphic CYP2D6. Side-chain oxidation is mediated mainly by CYP1A2 and to some extent by CYP2D6.
METABOLITE -> PARENT
URINE
METABOLITE ACTIVE -> PARENT
Metabolite to parent drug ratio in non-uraemic human plasma after chronic administration of parent drug.
METABOLITE TO PARENT DRUG RATIO
PLASMA; URINE
METABOLITE ACTIVE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC